
NASDAQHealthcareMedical - Specialties
أحدث البيانات المتاحة
6.855 US$
+0.815 US$ · +13.49%
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
الإغلاق السابق
6.855 US$
+0.815 US$ · +13.49%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
نطاق اليوم
السعر الحالي 6.855 US$
نطاق 52 أسبوعًا
السعر الحالي 6.855 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
82
قيمة جذابة جدًا
المشاعر
53
مختلط
المخاطر
71
مخاطر مرتفعة
الزخم
19
هبوط قوي
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
نطاق اليوم
السعر الحالي 6.855 US$
نطاق 52 أسبوعًا
السعر الحالي 6.855 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 43.79 مليون USD | 61.56 مليون USD | 56.83 مليون USD | 62.52 مليون USD | 81.15 مليون USD |
| تكلفة البضاعة المباعة | 26.9 مليون USD | 40.11 مليون USD | 37.38 مليون USD | 52.73 مليون USD | 54.89 مليون USD |
| الربح الإجمالي | 16.89 مليون USD | 21.44 مليون USD | 19.45 مليون USD | 22.05 مليون USD | 33.45 مليون USD |
| البحث والتطوير | 3.63 مليون USD | 4.54 مليون USD | 4.38 مليون USD | 4.14 مليون USD | 4.5 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 24.67 مليون USD | 28.82 مليون USD | 31.15 مليون USD | 29.17 مليون USD | 24.68 مليون USD |
| نفقات التشغيل | 28.3 مليون USD | 42.61 مليون USD | 46.5 مليون USD | 32.96 مليون USD | 29.52 مليون USD |
| دخل الفوائد | 221 ألف USD | — | 1.17 مليون USD | 303 ألف USD | 1.22 مليون USD |
| مصاريف الفوائد | 13.11 مليون USD | 9.57 مليون USD | 10.15 مليون USD | 24.73 مليون USD | 7.1 مليون USD |
| الاستهلاك والإطفاء | 2.68 مليون USD | 1.87 مليون USD | 1.78 مليون USD | 2.33 مليون USD | 2.74 مليون USD |
| الدخل التشغيلي | −11.42 مليون USD | −21.17 مليون USD | −27.05 مليون USD | −15.27 مليون USD | 3.94 مليون USD |
| صافي الدخل | −37.38 مليون USD | −31.79 مليون USD | −24.02 مليون USD | −41 مليون USD | 875 ألف USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.